TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01275014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: 1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
Study: NCT00611247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide
Study: NCT00825604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary angioplasty (PCI)
Description: optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
Study: NCT01199666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: text message appointment and immunization reminders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message
Description: text message appointment and immunization reminders
Study: NCT03567902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope intubation
Description: C-MAC videolaryngoscope intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope intubation
Description: C-MAC videolaryngoscope intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope intubation
Description: Direct laryngoscope intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope intubation
Description: Direct laryngoscope intubation
Study: NCT01722461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Ulthera System delivering no ultrasound energy
Study: NCT00620061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24
Description: 24 mcg capsules for oral administration
Study: NCT01948830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Description: 0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Description: 0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
Study: NCT01541293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
Study: NCT04235881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App REM volver a casa
Description: The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks.
Study: NCT03184480

Intervention type: DRUG
Intervention: Arnuity Ellipta
Description: The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
Study: NCT02214264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-Kindness meditation training
Description: Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Awareness meditation training
Description: Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude
Description: Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
Study: NCT03347032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Serial inflations and deflations as detailed in the arm/group descriptions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Serial inflations and deflations as detailed in the arm/group descriptions
Study: NCT03649971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab SC will be administered every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab SC will be administered every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC will be administered every 4 weeks.
Study: NCT03331497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Description: About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.
Study: NCT01532297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CiDi)
Description: Use during chronic dialysis 3x/week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CiDi)
Description: Use during chronic dialysis 3x/week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CiDi)
Description: Use during chronic dialysis 3x/week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysate (StDi)
Description: Use during chronic dialysis 3x/week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysate (StDi)
Description: Use during chronic dialysis 3x/week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysate (StDi)
Description: Use during chronic dialysis 3x/week
Study: NCT02877147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEBTC
Description: SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEBTC
Description: SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
Study: NCT02836847

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biological test
Description: mutation and signal pathway activation status analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological test
Description: mutation and signal pathway activation status analysis
Study: NCT00744302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physiological (1.25 mmol/L ) calcium dialysate
Description: Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: physiological (1.25 mmol/L ) calcium dialysate
Description: Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
Study: NCT02836847

Intervention type: DRUG
Group type: OTHER
Intervention: GEMOX
Description: Conventional chemotherapy:gemcitabine and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: Conventional chemotherapy:gemcitabine and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT03991039

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gamma knife
Description: Microvascular decompression

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gamma knife
Description: Microvascular decompression
Study: NCT01486433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg (1 tablet) simvastatin once a day
Study: NCT02200198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Description: Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
Study: NCT02836847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Study: NCT02200198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
Study: NCT01486433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg (1 tablet) simvastatin once a day
Study: NCT02836847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study: NCT01486433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Description: 81 mg aspirin (1 tablet), once a day, co-administered with simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Description: 81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
Study: NCT02836847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Study: NCT04724473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin Cream 0.025%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin Cream 0.025%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Cream 0.025%
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT00408967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucotuzumab celmoleukin (EMD 273066)
Study: NCT00374244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimozide
Description: half of the subjects are randomized to the active drug group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: half of the subjects are randomized to placebo group
Study: NCT01501279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
Study: NCT01232699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Obesity Treatment
Description: Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Obesity Treatment with MI
Description: In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
Study: NCT01486433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
Study: NCT01232699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent MI
Description: Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
Study: NCT02200198

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
Study: NCT04040322

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV infusion
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study: NCT03410511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine free intake
Description: The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine intake
Description: The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
Study: NCT04040322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iloprost Injection, for intravenous use
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study: NCT01883271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training
Description: Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous moderate intensity exercise
Description: Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
Study: NCT00574236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341, doxorubicin
Description: bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
Study: NCT03598517

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose chemoradiotherapy
Description: Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation.
Study: NCT03370705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: Sulodexide 250 ULS twice daily per oral route
Study: NCT03672604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide
Study: NCT01799330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Muscle Stimulation (TCEMS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham TCEMS
Description: Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
Study: NCT01732978

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Crying record
Description: Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff
Study: NCT02911597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
Study: NCT03370705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin 20mg once daily per oral route,
Study: NCT03410511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation intake
Description: The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
Study: NCT03082560

Intervention type: DIAGNOSTIC_TEST
Intervention: Boston Grade of Activity in Lichen Planopilaris
Description: A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
Study: NCT03657719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3114
Description: High-dose Quadrivalent influenza vaccine
Study: NCT00839605

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
Study: NCT03657719

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Quadrivalent
Description: Quadrivalent influenza vaccine
Study: NCT02149810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automatic Self Transcending Meditation
Description: as above
Study: NCT01576042

Intervention type: DRUG
Group type: OTHER
Intervention: amiodarone
Description: The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

Intervention type: DRUG
Group type: OTHER
Intervention: sotalol
Description: The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

Intervention type: DEVICE
Group type: OTHER
Intervention: Biosense Webster's NAVI-STAR Thermo-Cool
Description: The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
Study: NCT04150627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep breathing
Description: Deep breathing maneuver to increase parasympathetic nerve activity
Study: NCT03206177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Galunisertib 150mg po BID day 4-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Day 1: Paclitaxel 175 mg/m2 over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
Study: NCT02058797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherence Therapy
Description: Manualized individual treatment (3 + 1 one-hour sessions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Manualized individual treatment (3 + 1 one-hour sessions)
Study: NCT00724230

Intervention type: DRUG
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks.

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
Study: NCT04328597

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: Inguinal hernia repair (open, laparo-endoscopic, robotic)

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: Inguinal hernia repair (open, laparo-endoscopic, robotic)
Study: NCT00675597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
Description: Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
Study: NCT00004183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT04146922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step down to oral antimicrobial therapy
Description: Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV antimicrobial therapy
Description: No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.